Cathie Wood’s ARK Invest Buys Over 240,000 Shares of Fate Therapeutics
A couple of Cathie Wood's ARK Invest funds bought over 240,000 shares of Fate Therapeutics on August 3.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
A couple of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Tuesday. The fund bought over 240,000 shares of Fate Therapeutics Inc. (NASDAQ: FATE) altogether, as the price of these ETFs were somewhat mixed on the day. Note that these funds are up significantly in the past year.
Specifically, ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 55,163 shares of Fate Therapeutics, and ARK Innovation ETF (NYSEARCA: ARKK) bought 186,114 shares. At Tuesday’s closing price, this would have valued this purchase at roughly $20.1 million altogether. Even though this is a small fraction of the total holdings, every little bit counts. ARKG is up 50% in the past year and ARKK is up closer to 46%.
Here is a look at the other purchases across the ARK ETFs:
| Fund | Ticker | Company | Shares |
|---|---|---|---|
| ARKF | ETSY | Etsy | 90,831 |
| ARKF | HOOD | Robinhood Markets | 89,622 |
| ARKG | SRNG | Soaring Eagle Acquisition | 214,751 |
| ARKG | SMFR | Sema4 | 96,000 |
| ARKG | SGFY | Signify Health | 31,587 |
| ARKG | RPTX | Repare Therapeutics | 11,809 |
| ARKG | MASS | 908 Devices | 46,488 |
| ARKG | BEAM | Beam Therapeutics | 3,074 |
| ARKG | EDIT | Editas Medicine | 35,000 |
| ARKG | FATE | Fate Therapeutics | 55,163 |
| ARKK | VCYT | Veracyte | 16,379 |
| ARKK | PACB | Pacific Biosciences of California | 190,000 |
| ARKK | FATE | Fate Therapeutics | 186,114 |
| ARKK | BEAM | Beam Therapeutics | 37,694 |
| ARKQ | MKFG | Markforged | 397,767 |
| ARKQ | AVAV | Aerovironment | 22,232 |
| ARKW | CND | Conchord Acquisition | 3,000 |
| ARKW | KVSB | Khosla Ventures Acquisition II | 10,000 |
| ARKW | VUZI | Vuzix | 90,000 |
[nativounit]
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
[recirclink id=927148][wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics. Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications. A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.
